BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 21114416)

  • 1. Aleglitazar, a balanced PPARα/γ agonist, has no clinically relevant pharmacokinetic interaction with high-dose atorvastatin or rosuvastatin.
    Foley-Comer AJ; Young AM; Russell-Yarde F; Jordan P
    Expert Opin Investig Drugs; 2011 Jan; 20(1):3-12. PubMed ID: 21114416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disposition of atorvastatin, rosuvastatin, and simvastatin in oatp1b2-/- mice and intraindividual variability in human subjects.
    DeGorter MK; Urquhart BL; Gradhand U; Tirona RG; Kim RB
    J Clin Pharmacol; 2012 Nov; 52(11):1689-97. PubMed ID: 22167570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design.
    Polli JW; Hussey E; Bush M; Generaux G; Smith G; Collins D; McMullen S; Turner N; Nunez DJ
    Xenobiotica; 2013 Jun; 43(6):498-508. PubMed ID: 23256625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of aleglitazar on the pharmacokinetics and pharmacodynamics of S- and R-warfarin in healthy male subjects.
    Sanwald-Ducray P; Jamois C; Banken L
    J Cardiovasc Pharmacol; 2014 Feb; 63(2):152-7. PubMed ID: 24157957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolism, excretion, and pharmacokinetics of [14c]-radiolabeled aleglitazar: a phase I, nonrandomized, open-label, single-center, single-dose study in healthy male volunteers.
    Sturm S; Seiberling M; Weick I; Paehler A; Funk C; Ruf T
    Clin Ther; 2012 Feb; 34(2):420-9. PubMed ID: 22244809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
    Fonseca FA; Ruiz A; Cardona-Muñoz EG; Silva JM; Fuenmayor N; Marotti M;
    Curr Med Res Opin; 2005 Aug; 21(8):1307-15. PubMed ID: 16083541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic interaction between ezetimibe and rosuvastatin.
    Kosoglou T; Statkevich P; Yang B; Suresh R; Zhu Y; Boutros T; Maxwell SE; Tiessen R; Cutler DL
    Curr Med Res Opin; 2004 Aug; 20(8):1185-95. PubMed ID: 15324521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open-label, crossover study of the pharmacokinetics of Insoluble Drug Delivery-MicroParticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers.
    Penn R; Williams RX; Guha-Ray DK; Sawyers WG; Braun SL; Rains KT
    Clin Ther; 2006 Jan; 28(1):45-54. PubMed ID: 16490579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.
    Keskitalo JE; Zolk O; Fromm MF; Kurkinen KJ; Neuvonen PJ; Niemi M
    Clin Pharmacol Ther; 2009 Aug; 86(2):197-203. PubMed ID: 19474787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human skeletal muscle drug transporters determine local exposure and toxicity of statins.
    Knauer MJ; Urquhart BL; Meyer zu Schwabedissen HE; Schwarz UI; Lemke CJ; Leake BF; Kim RB; Tirona RG
    Circ Res; 2010 Feb; 106(2):297-306. PubMed ID: 19940267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin.
    Schneck DW; Birmingham BK; Zalikowski JA; Mitchell PD; Wang Y; Martin PD; Lasseter KC; Brown CD; Windass AS; Raza A
    Clin Pharmacol Ther; 2004 May; 75(5):455-63. PubMed ID: 15116058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of rosuvastatin/olmesartan fixed-dose combination: a single-dose, randomized, open-label, 2-period crossover study in healthy Korean subjects.
    Son H; Roh H; Lee D; Chang H; Kim J; Yun C; Park K
    Clin Ther; 2013 Jul; 35(7):915-22. PubMed ID: 23810276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No clinically relevant drug-drug interactions when dalcetrapib is co-administered with atorvastatin.
    Derks M; Abt M; Parr G; Meneses-Lorente G; Young AM; Phelan M
    Expert Opin Investig Drugs; 2010 Oct; 19(10):1135-45. PubMed ID: 20738227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine.
    Simonson SG; Raza A; Martin PD; Mitchell PD; Jarcho JA; Brown CD; Windass AS; Schneck DW
    Clin Pharmacol Ther; 2004 Aug; 76(2):167-77. PubMed ID: 15289793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-dose, 2-way crossover, bioequivalence study of two rosuvastatin formulations in normal healthy subjects under fasting conditions.
    Trabelsi F; Bartůnek A; Vlavonou R; Navrátilová L; Dubé C; Tanguay M; Hauser T
    Int J Clin Pharmacol Ther; 2012 Oct; 50(10):741-50. PubMed ID: 22762855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical equivalence of proprietary and generic atorvastatin in lipid clinic patients.
    Rahalkar AR; Ban MR; Hegele RA
    Can J Cardiol; 2013 Apr; 29(4):418-22. PubMed ID: 22840301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies.
    Pasha MK; Muzeeb S; Basha SJ; Shashikumar D; Mullangi R; Srinivas NR
    Biomed Chromatogr; 2006 Mar; 20(3):282-93. PubMed ID: 16143964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Not all statins interfere with clopidogrel during antiplatelet therapy.
    Mach F; Senouf D; Fontana P; Boehlen F; Reber G; Daali Y; de Moerloose P; Sigwart U
    Eur J Clin Invest; 2005 Aug; 35(8):476-81. PubMed ID: 16101667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coadministration of dalcetrapib with pravastatin, rosuvastatin, or simvastatin: no clinically relevant drug-drug interactions.
    Derks M; Abt M; Phelan M; Turnbull L; Meneses-Lorente G; Bech N; White AM; Parr G
    J Clin Pharmacol; 2010 Oct; 50(10):1188-201. PubMed ID: 20489031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.